Max Mikheev

Max Mikheev is the CEO and Founder of BioMediCan, Inc., a biotechnology company based in the San Francisco Bay Area.3 Here are some key details about Max Mikheev's background and experience:

Education and Early Career

Max Mikheev has an extensive educational background in molecular biology and medicine:

• PhD in Molecular Biology from the State Research Center of Virology and Biotechnology "Vector" (1998-2006)3
• MD in Clinical and Laboratory Diagnostics from Novosibirsk State Medical University (1999-2004)3
• M.Sc. in Molecular Biology from Novosibirsk State University (1994-1999)3

Professional Experience

BioMediCan, Inc.:

• Founder and CEO since November 20173
• The company focuses on developing production of high-value compounds through biosynthesis3

Previous Roles::

• Co-founder of Viar.Live, a VR software startup (2015-2017)3
• CTO and Co-founder of BioDatomics, a life sciences startup focused on big data analytics for genomics (2012-2017)3
• Postdoctoral Research Fellow at University of Pittsburgh School of Medicine (2008-2011)3
• Postdoctoral Research Fellow at National Institute on Aging (2006-2008)3

Expertise and Achievements

• Over 22 years of experience in genomics4
• Co-inventor of multiple patent applications related to genetic modifications4
• Co-founded BioDatomics, the first Hadoop-based big data genomic analysis platform4
• Co-founded BioSoft RU, a genomic pathways software startup4

Current Work at BioMediCan

At BioMediCan, Max Mikheev and his team have developed a cutting-edge biotechnology method called Biosynthesis.2 This method has revolutionized the production of high-value compounds like CBG, THCA, THCV, CBN, and rare cannabinoids.2 The company uses genetically optimized yeast to produce pharmaceutically pure cannabinoids that are identical to those found in nature, but at a fraction of the cost.2

Max Mikheev's role as CEO and Chief Science Officer involves shaping the company's scientific strategy and overseeing its research and development efforts.14 While he prefers to focus on the scientific aspects of the job, he has also played a significant role in raising capital for the company and working with investors.2